US Patent

US9192571 — Ketorolac tromethamine compositions for treating or preventing ocular pain

Formulation · Assigned to Allergan Inc · Expires 2028-03-07 · 2y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects an aqueous ophthalmic solution containing ketorolac and carboxymethyl cellulose for treating or preventing ocular pain.

USPTO Abstract

The present invention provides an aqueous ophthalmic solution with an effective amount of ketorolac and carboxymethyl cellulose in an aqueous solution which provides increased visual acuity and wherein the concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient that is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac.

Drugs covered by this patent

Patent Metadata

Patent number
US9192571
Jurisdiction
US
Classification
Formulation
Expires
2028-03-07
Drug substance claim
No
Drug product claim
Yes
Assignee
Allergan Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.